Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats.
Cholecystokinin (CCK) in the nervous system has effects opposite to those of opioids. However, the mechanism by which CCK opposes the effect of opioids at the receptor or cellular level is still unknown. In the brain, distributions of CCK receptors and opioid receptors have been demonstrated to overlap. The present study was undertaken to determine the mechanism of CCK-opioid interactions in the cortex of ovariectomized rats. Furthermore, because estrogen is a powerful regulator of CCK and opioid activity, we examined whether estrogen state also modulates the interactions of these neuropeptides. mu-Opioid (MOP) receptor binding was examined in cortical membranes that were preincubated with CCK-8S and CCK receptor agonist and antagonist followed with 3H-DAMGO. Pharmacological results revealed that CCK-8S suppressed 3H-DAMGO binding in cortical membranes of ovariectomized rats. The same result was obtained using a CCK1 receptor agonist (JMV-180), whereas a CCK2 receptor agonist (CCK-4) failed to suppress 3H-DAMGO binding. Antagonism of the CCK1 receptor by JMV-179 blocked both CCK-8S and JMV-180 suppression of 3H-DAMGO binding. Furthermore, estrogen treatment to female rats resulted in a suppression of 3H-DAMGO binding in cortical membranes. These results demonstrate an estrogen regulation of the MOP receptor and a protein-protein interaction between CCK1 receptor and MOP receptor.
Department of Neurobiology, Laboratory of Neuroendocrinology of the Brain Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1763, USA. aquesada@mednet.ucla.edu
Arnulfo
A
Quesada
Paul
P
Micevych
D000701:Analgesics, Opioid / Q000493:pharmacokinetics; D000704:Analysis of Variance; D000818:Animals; D016466:CHO Cells; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism*; D006224:Cricetinae; D003412:Cricetulus; D004347:Drug Interactions; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000493:pharmacokinetics; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D010052:Ovariectomy / Q000379:methods; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D011869:Radioligand Assay / Q000379:methods; D051381:Rats; D020318:Rats, Long-Evans; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D017450:Receptors, Opioid, mu / Q000378:metabolism*; D012844:Sincalide / Q000031:analogs & derivatives / Q000494:pharmacology; D014316:Tritium / Q000493:pharmacokinetics
D000701:Analgesics, Opioid; D004967:Estrogens; D006727:Hormone Antagonists; D011949:Receptors, Cholecystokinin; D017450:Receptors, Opioid, mu; D014316:Tritium; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C070096:JMV 179; C058451:JMV 180; D011377:Proglumide; C048181:lorglumide; D012844:Sincalide